Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Drug Pricing Reform In Medicaid: Watch This Space

Executive Summary

Some manufacturers may have to start essentially paying Medicaid programs to cover their drugs beginning in 2024 under a provision in the US economic relief bill headed to President Biden. 

You may also be interested in...



New Payment Models For Cell, Gene Therapies Unlikely To Originate With Medicare – Former Official

Risk-averse decision-making climate at CMS and a likely unwillingness to commit the resources needed probably means that innovative payment arrangements for cell and gene therapies may have to start in the commercial insurance sector, Demetrios Kouzoukas suggests.

Higher Medicaid Rebates For Expedited Approvals Offer Modest Savings But Target Growing Concern

As MACPAC moves toward formal recommendations, a CBO analysis finds that differential Medicaid rebates for drugs approved through the accelerated pathway could save the federal government up to $1bn over five years.

Don’t Let The Quiet Fool You: The US Drug Pricing Debate Is At A Critical Point

There won’t be a lot of legislative action in Congress in the weeks following passage of the $1.9tn American Rescue Plan. But the coming months are a critical time for the drug industry to try to set the terms for how it is treated in the next major bill later this year, and the stakes could not be higher.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS143962

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel